COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF UPADACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ACTIVE CROHN'S DISEASE IN GREECE

被引：0
|
作者：
Vellopoulou, K. [1 ]
Lioliou, K. [1 ]
Papantoniou, P. [2 ]
Kotsis, I [2 ]
机构：
[1] Econcare LP, Athens, Greece
[2] AbbVie Hellas, Athens, Greece
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE94
引用
收藏
页码：S72 / S72
页数：1
相关论文
共 50 条
  • [31] BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL IN THE MANAGEMENT OF PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS IN GREECE
    Tzanetakos, C.
    Maniadakis, N.
    Kourlaba, G.
    Tzioufas, A.
    Goules, A.
    Theodoratou, T.
    Christou, P.
    VALUE IN HEALTH, 2014, 17 (07) : 375 - 375
  • [32] BUDGET-IMPACT AND COST-EFFECTIVENESS OF TILDRAKIZUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS FROM A US HEALTH PLAN PERSPECTIVE
    Carrico, J.
    Jia, X.
    Zhao, Y.
    Zhang, J.
    Brodtkorb, T. H.
    Mendelsohn, A. B.
    Lowry, S.
    Wu, J. J.
    Feldman, S. R.
    Armstrong, A. W.
    VALUE IN HEALTH, 2019, 22 : S52 - S52
  • [33] BUDGET IMPACT ANALYSIS OF APREMILAST IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Solakidi, A.
    Tzanetakos, C.
    Kourlaba, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2018, 21 : S424 - S425
  • [34] The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritis
    Avci, Ali Berkant
    Feist, Eugen
    Burmester, Gerd Rudiger
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021, 13
  • [35] COST-EFFECTIVENESS OF BRODALUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE
    Solakidi, A.
    Tzanetakos, C.
    Kontodimas, S.
    Kourlaba, G.
    VALUE IN HEALTH, 2018, 21 : S428 - S428
  • [36] Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis
    Wu, Bin
    Wang, Zhenhua
    Zhang, Qiang
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (11) : 2291 - 2302
  • [37] Cost-effectiveness of tacrolimus for the treatment of moderate-to-severe lupus nephritis in China
    Kim, Soyoung
    Ooi, Adrian Yit Reen
    Stephens, Thomas
    Jiang, Hongsi
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (13) : 1125 - 1141
  • [38] Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States
    Jia, Xiaoying
    Zhao, Yang
    Carrico, Justin
    Brodtkorb, Thor-Henrik
    Mendelsohn, Alan M.
    Lowry, Simon
    Feldman, Steve
    Wu, Jashin J.
    Armstrong, April W.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 740 - 748
  • [39] Consistency of treatment benefit with infliximab in patients with moderate-to-severe active Crohn's disease
    Vasiliauskas, E
    Targan, S
    Sands, B
    Hanauer, S
    Mayer, L
    Present, D
    Braakman, T
    DeWoody, K
    Schaible, T
    Rutgeerts, P
    GASTROENTEROLOGY, 1999, 116 (04) : A837 - A837
  • [40] Cost-Utility Analysis of Biologic Treatments for Moderate-to-Severe Crohn's Disease
    Tang, Derek H.
    Armstrong, Edward P.
    Lee, Jeannie K.
    PHARMACOTHERAPY, 2012, 32 (06): : 515 - 526
12345